Clinical trials: Cervix; Pregnancy
Uterine Cervical Neoplasms
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix.
- Trial name
- NCT02509585
- Testing
- Tc99m tilmanocept
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Cardinal Health 414, LLC
Pleuropulmonary Blastoma, Cystic Nephroma
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB are not defined.
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma
- Trial name
- PPB (NCT00565903)
- Where
- United States
- Volunteers
- 1,247 people, healthy volunteers welcome
- Sponsor
- Ashley Hill
Healthy
Sonographic Prediction of Preterm Delivery Between 24-34 Weeks of Gestation
to evaluate if sonographic measure of short uterin cervix, sludge in amniotic fluid and abnormal doppler of the uterin artery can predict preterm labor
- Trial name
- NCT00613210
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Cervix Carcinoma
Radiotherapy + Metronidazole vs Radiotherapy Alone In Improving Treatment Outcomes in Advanced Cervical Cancer in Uganda
The objective of the study was to determine whether there was a difference in the effectiveness of Radiotherapy alone compared with Radiotherapy plus Metronidazole in the treatment of women with advanced cancer of the cervix in…
- Trial name
- NCT01937650
- Testing
- Radiotherapy plus metronidazole
- Volunteers
- 38 people
- Sponsor
- Makerere University
Atypical Squamous Cell of Undetermined Significance, ASC-US
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
This study compares the efficacy of cytology (Pap smear) with the molecular screening in their ability to detect reactive cellular changes in the cervix among an open population
- Conditions
- Atypical Squamous Cell of Undetermined Significance, ASC-US, Atypical Glandular Cells of Uncertain Significance, AGUS
- Trial name
- NCT07211204
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Breast Neoplasms, Endometrial Neoplasms
Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers
Thermal therapy (hyperthermia of heat) can increase the effect of chemotherapy treatments. By itself, thermal therapy can also kill cancer cells.
- Conditions
- Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00178802
- Testing
- thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women.
- Conditions
- High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection
- Trial name
- NCT07572396
- Testing
- EGCG and Quinine Sulfate Vaginal Suppository
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- Amplexd Therapeutics, Inc.
Preterm Birth
Cerclage for Singletons With Short Cervix Without Prior Preterm Birth
Preterm birth remains the most common cause of perinatal morbidity and mortality. A short cervi- cal length on transvaginal ultrasonography has been shown to be one of the best predictors of preterm birth.
- Trial name
- NCT02716922
- Testing
- Cervical cerclage
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Federico II University
Cervical Cancer
Docetaxel in Treating Patients With Advanced Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with advanced cancer of…
- Trial name
- NCT00003445
- Testing
- docetaxel
- Where
- Argentina
- Sponsor
- Grupo Oncologico Cooperativo del Sur
Cervix; Pregnancy
Comparative Study Between Only Vaginal Misoprostol and Vaginal Misoprostol and Estradiol Cream
To compare the safety and effectiveness of vaginal misoprostol with combined vaginal misoprostol and estradiol for induction of labour in unfavorable cervix
- Trial name
- NCT05306405
- Testing
- Vaginal Tablet
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Uterine Cervical Neoplasms
A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix
The investigators design a phase 2, open labeled, randomized trial of Tamoxifen (20 mg/day) and Letrozole (2.5 mg) in treatment of squamous carcinoma of the cervix.
- Trial name
- TGOG1005 (NCT02482740)
- Testing
- Letrozole, tamoxifen
- Where
- 7 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Uterine Cervical Neoplasms
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Indication: Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior radiochemotherapy or neo-adjuvant chemotherapy is allowed.
- Trial name
- NCT02009579
- Testing
- Nintedanib
- Where
- 32 sites in Belgium, Germany and 2 more
- Volunteers
- 120 people
- Sponsor
- Belgian Gynaecological Oncology Group